利奈唑胺联合环丝氨酸在耐药肺结核患者中的治疗效果及对血清白介素-6、γ干扰素水平的影响

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (586 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the therapeutic effect of Linezolid combined with Cycloserine in drug-resistant pulmonary tuberculosis patients and the effect on serum interleukin-6 (IL-6) and γ interferon (IFN-γ) levels.Methods A total of 82 patients with drug-resistant pulmonary tuberculosis admitted to Second Hospital of Longyan City,Fujian Province from December 2017 to December 2020 were selected and divided into study group and control group according to the random number table method,with 41 cases in each group.The control group was treated with Cycloserine,and the study group was treated with Cycloserine + Linezolid,both of which continued to be treated for 6 months.The clinical efficacy,recovery of clinical symptoms,IL-6,IFN-γ and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the study group was higher than that in the control group,the absorption of lesions,sputum culture and acid-fast staining smears were shorter than those in the control group,and the differences were statistically significant (P<0.05).Before treatment,there was no significant difference in serum IL-6 and IFN-γ levels between the two groups (P>0.05);after treatment,the serum IL-6 and IFN-γ levels in the study group were lower than those in the control group,and the differences were statistically significant (P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).Conclusion Linezolid combined with Cycloserine is effective in the treatment of drug-resistant pulmonary tuberculosis.It can improve the clinical symptoms of patients,reduce serum IL-6 and IFN-γ levels,and is safe and reliable.

Key words： Drug-resistant tuberculosis Linezolid Cycloserine Serum interleukin-6 Interferon-&gamma

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LAI Jinmei
	LUO lanyu
	LIU Jinhua

Cite this article:

LAI Jinmei,LUO lanyu,LIU Jinhua. Therapeutic effect of Linezolid combined with Cycloserine in patients with drug-resistant pulmonary tuberculosis and its effect on serum interleukin-6 and γ interferon levels[J]. 中国当代医药, 2022, 29(14): 55-57-62.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I14/55

[1]	邢小明，许优，李积安.结核丸联合环丝氨酸治疗耐药性肺结核效果及对患者炎性因子水平的影响[J].药物评价研究，2019，42（6）：1180-1183.
[2]	李毅，席素雅，石庆芳，等.黄芪注射液联合西药对单耐药肺结核患者抗炎、促炎因子及免疫调节作用研究[J].辽宁中医药大学学报，2019，21（8）：149-152.
[3]	张凯，张勇，韦洁，等.金水宝联合含环丝氨酸化疗方案对耐多药肺结核患者免疫功能的调节[J].中国临床研究，2020，33（4）：528-530，535.
[4]	付康，宋晓燕，张天钰.含环丝氨酸联合胸腺肽方案治疗耐多药肺结核的疗效及安全性[J].临床和实验医学杂志，2018，17（24）：2643-2646.
[5]	中华医学会结核病学分会，结核病病理学诊断专家共识编写组.中国结核病病理学诊断专家共识[J].中华结核和呼吸杂志，2017，40（6）：419-425.
[6]	张萌涛，许优，马进宝.利奈唑胺联合环丝氨酸胶囊和左氧氟沙星治疗耐药肺结核的疗效及机制分析[J].河北医学，2018，24（8）：1304-1307.
[7]	代晓琦，李仁忠，阮云洲，等.异烟肼对利福平单耐/多耐药肺结核患者治疗效果的分析[J].中国防痨杂志，2018，40（6）：564-569.
[8]	刘幸，欧阳兵，李娜，等.中西医结合治疗耐多药肺结核的疗效及经济学评价[J].昆明医科大学学报，2020，41（11）：49-55.
[9]	周妍卉，刘先军，熊畅，等.利福喷丁对肺结核患者血清IL-6、IFN-γ、CA125 水平的影响[J].现代生物医学进展，2018，18（21）：4118-4121.
[10]	张会强，文政芳，张冬杰，等.IFN-γ 及血清炎症因子水平变化与肺结核发病相关性及作用机制分析[J].中华医院感染学杂志，2019，29（2）：184-187.
[11]	陈永宏，向江琳，肖江峰，等.环丝氨酸联合胸腺肽治疗耐多药肺结核的效果[J].中华医院感染学杂志，2019，29（17）：2643-2647.
[12]	王敬，荆玮，陈维，等.含环丝氨酸方案治疗耐多药肺结核患者发生不良反应的临床分析[J].中国防痨杂志，2018，40（8）：810-814.
[13]	常苗苗，西娜，赵乙丞，等.221 例结核科住院患者利奈唑胺的应用分析[J].中国药物应用与监测，2020，17（6）：403-407.
[14]	高岭，任鹏飞，常娅莉，等.利奈唑胺/环丝氨酸对耐多药肺结核患者细胞免疫及体液免疫的影响及安全性评价[J].中国免疫学杂志，2020，36（14）：1735-1739.
[15]	邓飞，王勇.利奈唑胺对耐药肺结核患者血清降钙素原、红细胞沉降率及C 反应蛋白的影响[J].四川医学，2018，39（7）：801-804.
[16]	曾安津，范天琼，杨成明，等.利奈唑胺联合环丝氨酸治疗耐多药肺结核患者的临床效果[J].中国当代医药，2021，28（22）：194-196，200.
[17]	袁科，张晓燕.利奈唑胺治疗重症肺炎的疗效评价及对患者血清IL-1β，TGF-β 和TNF-α 水平的影响[J].中国医药科学，2020，10（4）：60-62.